journal
MENU ▼
Read by QxMD icon Read
search

Gynecologic Oncology

journal
https://www.readbyqxmd.com/read/28811045/laparoscopic-dissection-of-female-pelvis-in-10-steps
#1
Krzysztof Gałczyński, Pauline Chauvet, Helder Ferreira, Nicolas Bourdel
No abstract text is available yet for this article.
August 12, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28807367/an-evaluation-of-progression-free-survival-and-overall-survival-of-ovarian-cancer-patients-with-clear-cell-carcinoma-versus-serous-carcinoma-treated-with-platinum-therapy-an-nrg-oncology-gynecologic-oncology-group-experience
#2
Kate E Oliver, William E Brady, Michael Birrer, David M Gershenson, Gini Fleming, Larry J Copeland, Krishnansu Tewari, Peter A Argenta, Robert S Mannel, Angeles Alvarez Secord, Jean-Marie Stephan, David G Mutch, Frederick B Stehman, Franco M Muggia, Peter G Rose, Deborah K Armstrong, Michael A Bookman, Robert A Burger, John H Farley
PURPOSE: We examined disparities in prognosis between patients with ovarian clear cell carcinoma (OCCC) and serous epithelial ovarian cancer (SOC). METHODS: We reviewed data from FIGO stage I-IV epithelial ovarian cancer patients who participated in 12 prospective randomized GOG protocols. Proportional hazards models were used to compare progression-free survival (PFS) and overall survival (OS) by cell type (clear cell versus serous). RESULTS: There were 10,803 patients enrolled, 9531 were eligible, evaluable and treated with platinum, of whom 544 (6%) had OCCC, 7054 (74%) had SOC, and 1933 (20%) had other histologies and are not included further...
August 11, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28807366/prospective-screening-with-the-validated-opioid-risk-tool-demonstrates-gynecologic-oncology-patients-are-at-low-risk-for-opioid-misuse
#3
Christine Garcia, Carolyn Lefkowits, Elizabeth Pelkofski, Leslie Blackhall, Linda R Duska
OBJECTIVE: To characterize risk for opioid misuse among gynecologic oncology patients. METHODS: The Opioid Risk Tool (ORT), a validated screen for opioid misuse risk, was administered to a convenience sample of patients with gynecologic cancer receiving opioid prescriptions in gynecologic oncology or palliative care clinics from January 2012-June 2016. Demographic and clinical information was abstracted on chart review. The primary outcome was ORT risk level (low vs...
August 11, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28803748/management-and-prognosis-of-ovarian-yolk-sac-tumors-an-analysis-of-the-national-cancer-data-base
#4
Dimitrios Nasioudis, Eloise Chapman-Davis, Melissa K Frey, Thomas A Caputo, Kevin Holcomb
OBJECTIVE: To evaluate the clinico-pathological characteristics, management and prognosis of women diagnosed with ovarian yolk sac tumors (OYSTs). METHODS: The U.S National Cancer Data Base was queried for women diagnosed with OYST between 2004 and 2014. Overall survival (OS) was calculated following generation of Kaplan-Meir curves. Univariate analysis was performed with the log-rank test. A Cox model was constructed to determine independent predictors of mortality...
August 10, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28802766/a-phase-i-trial-of-intraperitoneal-gen-1-an-il-12-plasmid-formulated-with-peg-pei-cholesterol-lipopolymer-administered-with-pegylated-liposomal-doxorubicin-in-patients-with-recurrent-or-persistent-epithelial-ovarian-fallopian-tube-or-primary-peritoneal-cancers
#5
REVIEW
Premal H Thaker, William E Brady, Heather A Lankes, Kunle Odunsi, William H Bradley, Kathleen N Moore, Carolyn Y Muller, Khursheed Anwer, Russell J Schilder, Ronald D Alvarez, Paula M Fracasso
OBJECTIVE: The study's purpose was to assess safety and efficacy of escalating doses of weekly GEN-1 with pegylated liposomal doxorubicin (PLD) in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers (EOC). METHODS: Patients had persistent or recurrent platinum-resistant EOC. The trial was a standard 3+3 phase I dose escalation design with patients receiving intravenous PLD 40mg/m(2) (dose level 1 and 2) or 50mg/m(2) (dose level 3) every 28days and intraperitoneal GEN-1 at 24mg/m(2) (dose level 1) or 36mg/m(2) (dose level 2 and 3) on days 1, 8, 15, and 22 of a 28day cycle...
August 9, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28802765/disparities-in-care-for-elderly-women-with-endometrial-cancer-adversely-effects-survival
#6
Anna Torgeson, Dustin Boothe, Matthew M Poppe, Gita Suneja, David K Gaffney
PURPOSE: Elderly women with endometrial cancer are at increased risk of local recurrence and cancer-specific death compared to younger women. We sought to investigate adjuvant radiotherapy (RT) practice patterns and effects on survival in elderly women with endometrial cancer. METHODS: Women from the National Cancer Data Base (NCDB) with FIGO IA grade 3 to FIGO IVA endometrial cancer diagnosed from 2004-2013 were included. Chi square analysis was used to compare the elderly (80+) and non-elderly women (18-79) and women who received RT and those that did not...
August 9, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28800945/impact-of-age-at-diagnosis-on-racial-disparities-in-endometrial-cancer-patients
#7
Christopher M Tarney, Chunqiao Tian, Guisong Wang, Elizabeth A Dubil, Nicholas W Bateman, John K Chan, Mohamed A Elshaikh, Michele L Cote, Joellen M Schildkraut, Craig D Shriver, Thomas P Conrads, Chad A Hamilton, G Larry Maxwell, Kathleen M Darcy
INTRODUCTION: Although black patients with endometrial cancer (EC) have worse survival compared with white patients, the interaction between age/race has not been examined. The primary objective was to evaluate the impact of age at diagnosis on racial disparities in disease presentation and outcome in EC. METHODS: We evaluated women diagnosed with EC between 1991 and 2010 from the Surveillance, Epidemiology, and End Results. Mutation status for TP53 or PTEN, or with the aggressive integrative, transcript-based, or somatic copy number alteration-based molecular subtype were acquired from the Cancer Genome Atlas...
August 8, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28800944/systematic-review-tumor-associated-antigen-autoantibodies-and-ovarian-cancer-early-detection
#8
REVIEW
Renée Turzanski Fortner, Antje Damms-Machado, Rudolf Kaaks
OBJECTIVES: Tumor-associated autoantibodies (AAbs), produced as an immune response to tumor-associated antigens (TAAs), are a novel pathway of early detection markers. METHODS: We conducted a systematic review on AAbs and ovarian cancer to summarize the diagnostic performance of individual AAbs and AAb panels. A total of 29 studies including 85 AAbs were included; 27 of the studies were conducted in prevalent cases and cancer-free controls and 2 investigations included pre-diagnosis samples...
August 8, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28800943/genetic-consultation-embedded-in-a-gynecologic-oncology-clinic-improves-compliance-with-guideline-based-care
#9
Leigha Senter, David M O'Malley, Floor J Backes, Larry J Copeland, Jeffery M Fowler, Ritu Salani, David E Cohn
OBJECTIVE: Analyze the impact of embedding genetic counseling services in gynecologic oncology on clinician referral and patient uptake of cancer genetics services. METHODS: Data were reviewed for a total of 737 newly diagnosed epithelial ovarian cancer patients seen in gynecologic oncology at a large academic medical center including 401 from 11/2011-7/2014 (a time when cancer genetics services were provided as an off-site consultation). These data were compared to data from 8/2014-9/2016 (n=336), when the model changed to the genetics embedded model (GEM), incorporating a cancer genetic counselor on-site in the gynecologic oncology clinic...
August 8, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28800942/plasma-and-ovarian-tissue-sphingolipids-profiling-in-patients-with-advanced-ovarian-cancer
#10
Paweł Knapp, Lubomir Bodnar, Agnieszka Błachnio-Zabielska, Magdalena Świderska, Adrian Chabowski
PURPOSE: The role of lipids in carcinogenesis through induction of abnormal cell lines in the human body is currently undisputable. Based on the literature, bioactive sphingolipids play an essential role in the development and progression of cancer and are involved in the metastatic process. The aim of this study was to determine the concentration of selected sphingolipids in patients with advanced ovarian cancer (AOC, FIGO III/IV, high grade ovarian cancer). METHODS: Seventy-four patients with ovarian cancer were enrolled...
August 8, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28800941/survival-and-safety-associated-with-aggressive-surgery-for-stage-iii-iv-epithelial-ovarian-cancer-a-single-institution-observation-study
#11
Shinichi Tate, Kazuyoshi Kato, Kyoko Nishikimi, Ayumu Matsuoka, Makio Shozu
OBJECTIVE: We evaluated the efficacy and safety of aggressive surgery for advanced ovarian cancer at a non-high-volume center. MATERIALS AND METHODS: We evaluated consecutive patients with stage III/IV ovarian, fallopian, and peritoneal cancer undergoing elective aggressive surgery from January 2008 to December 2012, which encompassed the first 5years after implementing an aggressive surgery protocol. After receiving appropriate training for 9months, a gynecological surgical team began performing multi-visceral resections...
August 8, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28800940/neoadjuvant-chemotherapy-and-chemotherapy-cycle-number-a-national-multicentre-study
#12
Alon D Altman, Jacob McGee, Taymaa May, Kelly Lane, Lin Lu, Wei Xu, Prafull Ghatage, Barry Rosen
OBJECTIVES: Six cycles of consolidation chemotherapy have become the standard for ovarian cancer treatment regimen following primary cytoreduction, yet with neoadjuvant chemotherapy (NAC), only 3 consolidation cycles are used. This study examines the effects of number of chemotherapy cycles in women with ovarian cancer that are being treated with neoadjuvant chemotherapy. In addition, we examined the effect of number of cycles on survival on consolidation and total chemotherapy. METHODS: All patients with stage IIIC and IV high grade serous carcinoma (HGSC) were identified at 4 major Canadian cancer centers treated with NAC...
August 8, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28797698/prognostic-value-of-lymph-node-ratio-and-number-of-positive-inguinal-nodes-in-patients-with-vulvar-cancer
#13
Stephan Polterauer, Richard Schwameis, Christoph Grimm, Ronalds Macuks, Sara Iacoponi, Kamil Zalewski, Ignacio Zapardiel
OBJECTIVE: To estimate the prognostic significance of lymph node ratio and number of positive nodes in vulvar cancer patients. METHODS: This international multicenter retrospective study included patients diagnosed with vulvar cancer treated with inguinal lymphadenectomy. Lymph node ratio (LNR) is the ratio of the number of positive lymph nodes (LN) to the number of removed LN. Patients were stratified into risk groups according to LNR. LNR was correlated with clinical-pathological parameters...
August 7, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28797697/changes-in-inflammatory-endometrial-cancer-risk-biomarkers-in-individuals-undergoing-surgical-weight-loss
#14
Faina Linkov, Sharon L Goughnour, Tianzhou Ma, Zhongying Xu, Robert P Edwards, Anna E Lokshin, Ramesh C Ramanathan, Giselle G Hamad, Carol McCloskey, Dana H Bovbjerg
OBJECTIVE: Obesity has been strongly linked to endometrial cancer (EC) risk. A number of potential EC risk biomarkers have been proposed, including heightened pro-inflammatory cytokines and adipokines. To evaluate if bariatric surgery can serve as a means for altering levels of such EC risk biomarkers, we investigated changes in these biomarkers after weight loss. METHODS: Blood samples were collected pre-operatively and 6months post-operatively in 107 female bariatric surgery patients aged 18-72years...
August 7, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28784245/the-effect-of-a-multidisciplinary-palliative-care-initiative-on-end-of-life-care-in-gynecologic-oncology-patients
#15
Mary M Mullen, Laura M Divine, Bree P Porcelli, Ivy Wilkinson-Ryan, Maria C Dans, Matthew A Powell, David G Mutch, Andrea R Hagemann, Premal H Thaker
OBJECTIVES: To evaluate the effect of palliative care (PC) consultation on hospice enrollment and end-of-life care in gynecologic oncology patients. METHODS: A retrospective chart review of gynecologic oncology patients who died 1year before and after 2014 implementation of a PC initiative for patients at a single NCI-designated comprehensive cancer center. Patient demographics, admission and procedural history, anti-cancer therapy, and end-of- life care were collected retrospectively...
August 4, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28779965/assessing-the-risk-of-pelvic-and-para-aortic-nodal-involvement-in-apparent-early-stage-ovarian-cancer-a-predictors-and-nomogram-based-analyses
#16
Giorgio Bogani, Elena Tagliabue, Antonino Ditto, Mauro Signorelli, Fabio Martinelli, Jvan Casarin, Valentina Chiappa, Giulia Dondi, Umberto Leone Roberti Maggiore, Cono Scaffa, Chiara Borghi, Luca Montanelli, Domenica Lorusso, Francesco Raspagliesi
OBJECTIVE: To estimate the prevalence of lymph node involvement in early-stage epithelial ovarian cancer in order to assess the prognostic value of lymph node dissection. METHODS: Data of consecutive patients undergoing staging for early-stage epithelial ovarian cancer were retrospectively evaluated. Logistic regression and a nomogram-based analysis were used to assess the risk of lymph node involvement. RESULTS: Overall, 290 patients were included...
August 2, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28774462/cytoreduction-of-bulky-para-aortic-lymphadenopathy-from-metastatic-ovarian-cancer
#17
Chahien Choi, Woo Young Kim, Dong Hee Lee, Sam Sae Oh
No abstract text is available yet for this article.
July 31, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28774461/phase-ii-trial-of-bevacizumab-with-dose-dense-paclitaxel-as-first-line-treatment-in-patients-with-advanced-ovarian-cancer
#18
Nicole D Fleming, Robert L Coleman, Celestine Tung, Shannon N Westin, Wei Hu, Yunjie Sun, Priya Bhosale, Mark F Munsell, Anil K Sood
OBJECTIVES: To assess the tolerability and efficacy of bevacizumab with carboplatin and weekly paclitaxel as first-line adjuvant therapy for advanced stage ovarian cancer. METHODS: After IRB approval, this single-institution, phase II study enrolled patients with stage III or IV epithelial ovarian cancer after primary cytoreductive surgery to treatment with carboplatin (AUC 5), weekly paclitaxel (80mg/m2), and bevacizumab (15mg/kg) every 3weeks for at least 6cycles...
July 31, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28768570/primary-cytoreductive-surgery-and-adjuvant-hormonal-monotherapy-in-women-with-advanced-low-grade-serous-ovarian-carcinoma-reducing-overtreatment-without-compromising-survival
#19
Amanda N Fader, Jennifer Bergstrom, Amelia Jernigan, Edward J Tanner, Kara Long Roche, Rebecca L Stone, Kimberly L Levinson, Stephanie Ricci, Stephanie Wethingon, Tian-Li Wang, Ie-Ming Shih, Bin Yang, Gloria Zhang, Deborah K Armstrong, Stephanie Gaillard, Chad Michener, Robert DeBernardo, Peter G Rose
OBJECTIVES: Women with advanced-stage, low-grade serous ovarian carcinoma (LGSC) have low chemotherapy response rates and poor overall survival. Most LGSC tumors overexpress hormone receptors, which represent a potential treatment target. Our study objective was to determine the outcomes of patients with advanced-stage LGSC treated with primary cytoreductive surgery (CRS) and hormone therapy (HT). METHODS: A retrospective study was performed at two academic cancer centers...
July 30, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28760368/is-adjuvant-chemotherapy-beneficial-for-surgical-stage-i-ovarian-clear-cell-carcinoma
#20
Liat Hogen, Harry Brar, Allan Covens, Dina Bassiouny, Marcus Q Bernardini, Lilian T Gien, Sarah E Ferguson, Danielle Vicus
Objective To assess the impact of adjuvant chemotherapy on survival in patients with surgical stage I ovarian clear cell carcinoma (OCCC). METHODS: Data collection and analysis of surgical stage I OCCC patients treated at two tertiary cancer centers was performed. Descriptive statistics, univariate and multivariable analyses and Kaplan-Meier survival probability estimates were completed. RESULTS: Sixty stage I OCCC patients who underwent comprehensive surgical staging were identified...
July 28, 2017: Gynecologic Oncology
journal
journal
23122
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"